Stryker price target raised to $320 from $292 at Jefferies

Jefferies analyst Matthew Taylor raised the firm’s price target on Stryker to $320 from $292 and keeps a Buy rating on the shares. The analyst sees "sea changes" in orthopedics due to the increased use of robotic surgery and a push to move more hip and knee procedures into outpatient settings. Stryker is the best way to play this theme, although all players can benefit, the analyst tells investors in a research note. The firm sees the ortho recovery continuing.